RMD Open

Cellular and molecular basis of neuropathic pain

Neuropathic pain is a devastating type of pain that significantly reduces the quality of life of affected people.
RMD Open

Autoantibody biomarkers and first-line therapy response in RA: findings from the CAP48 cohort

Objective A panel of antibodies against three antigens, University Hasselt (UH)-rheumatoid arthritis (RA).305, 318 and 329, has been associated with lack of response to first-line therapy in the Care ...
rmdopen.bmj

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Objective Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). We report the largest integrated safety analysis of tofacitinib, as of March 2017, using ...
rmdopen.bmj

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a ...

Objective Proactive therapeutic drug monitoring (pTDM) intends to optimise tumour necrosis factor (TNF) inhibitor treatment through regular assessment of drug and antidrug antibody levels, enabling ...
rmdopen.bmj

Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Introduction Interstitial lung disease (ILD) is a serious extra-articular manifestation of rheumatoid arthritis (RA) associated with increased morbidity and mortality. The pulmonary safety of biologic ...
rmdopen.bmj

Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis

Objective To study the effect of methotrexate (MTX) therapy on new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis (JIA). Methods In this matched case–control study, we ...
rmdopen.bmj

Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis

Objectives This study aimed to evaluate the risk of tuberculosis associated with the use of Janus kinase (JAK) inhibitors or biological disease-modifying antirheumatic drugs (bDMARDs) in patients ...
rmdopen.bmj

Global, regional and national trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the global burden of disease study 2021

Background Rheumatoid arthritis (RA) poses a significant global health challenge. This study examined trends in the incidence, prevalence and mortality of RA from 1990 to 2021 at global, regional and ...
rmdopen.bmj

Differences in treatment response between female and male psoriatic arthritis patients during IL-12/23 therapy with or without methotrexate: post hoc analysis of results from ...

Background The influence of sex on treatment outcomes during interleukin-12/23 therapy in patients with psoriatic arthritis (PsA) has not been explored. Objective To conduct exploratory post hoc ...
rmdopen.bmj

Fibromyalgia and mortality: a systematic review and meta-analysis

Objective To conduct a systematic review of the literature on the association between fibromyalgia and mortality and to pool the results in a meta-analysis. Methods The authors searched the PubMed, ...
rmdopen.bmj

Elevated serum levels of interleukin-18 discriminate Still’s disease from other autoinflammatory conditions: results from the European ImmunAID cohort

Objectives Systemic autoinflammatory diseases (SAIDs) represent a set of conditions with exaggerated innate immune responses. IL-1β and IL-18 are key cytokines involved in the pathogenesis of some ...